10% Owner Mark Strome Buys $200K in Zivo Bioscience Stock at Premium
Summary
A 10% owner of Zivo Bioscience, Mark E. Strome, purchased $200,000 worth of company stock in an open market transaction at a price significantly above the current market value.
Key Events
-
Significant Insider Purchase
Mark E. Strome, a 10% owner, acquired 100,000 shares of Zivo Bioscience common stock for a total of $200,000 in an open market purchase on April 17, 2026.
-
Purchase at Premium to Market
The shares were acquired at $2.00 per share, which is a significant premium compared to the current stock price of $1.20, indicating strong confidence from the reporting owner.
-
Increased Ownership Stake
Following this transaction, Strome Mark E's indirect holdings in Zivo Bioscience, Inc. increased to 572,942 shares.
Analysis
Mark E. Strome, a 10% owner of Zivo Bioscience, made a significant open market purchase of $200,000 in company stock. This transaction is particularly notable as the shares were acquired at $2.00 each, which is a substantial premium to the current stock price of $1.20. Such a purchase by a major shareholder, especially at a higher price than the prevailing market, signals strong conviction in the company's future prospects and adds to the recent pattern of insider accumulation.
At the time of this filing, ZIVO was trading at $1.20 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $1.11 to $22.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.